Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Other Non Operating Income (2021 - 2025)

Historic Other Non Operating Income for Oncology Institute (TOI) over the last 5 years, with Q3 2025 value amounting to -$6.0 million.

  • Oncology Institute's Other Non Operating Income fell 1076727.27% to -$6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.1 million, marking a year-over-year decrease of 102238.6%. This contributed to the annual value of $2.7 million for FY2024, which is 20717.54% up from last year.
  • As of Q3 2025, Oncology Institute's Other Non Operating Income stood at -$6.0 million, which was down 1076727.27% from -$4.0 million recorded in Q2 2025.
  • Oncology Institute's Other Non Operating Income's 5-year high stood at $15.5 million during Q3 2022, with a 5-year trough of -$6.0 million in Q3 2025.
  • Moreover, its 5-year median value for Other Non Operating Income was $54000.0 (2021), whereas its average is $1.1 million.
  • In the last 5 years, Oncology Institute's Other Non Operating Income soared by 2862222.22% in 2022 and then plummeted by 1076727.27% in 2025.
  • Oncology Institute's Other Non Operating Income (Quarter) stood at -$229000.0 in 2021, then soared by 3894.76% to $8.7 million in 2022, then tumbled by 113.3% to -$1.2 million in 2023, then soared by 111.16% to $129000.0 in 2024, then plummeted by 4733.33% to -$6.0 million in 2025.
  • Its last three reported values are -$6.0 million in Q3 2025, -$4.0 million for Q2 2025, and -$3.3 million during Q1 2025.